Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease.

[1] In 2017 its development was abandoned by Merck.

[2] In 2017 REVEAL trial anacetrapib was shown to decrease the risk of repeat heart attacks in high-risk patients with previous acute coronary events.

[3] Other CETP inhibitors:[citation needed]